• Skip to main content
  • Skip to primary sidebar
  • Home
  • News
  • Events
  • Education
  • Interviews
    • Career spotlight
  • Opinion
    • Professional Dilemmas
    • Patient perspective
  • PIPcast
  • Jobs
  • Business Directory

Pharmacy in Practice

EDX/20/1154
Date of prep: December 2020

Prescribing information and
adverse events reporting

For healthcare professionals only

Your responsibility when using NICE guidelines

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or the people using their service. It is not mandatory to apply the recommendations, and the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardian.

 

All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.

 

Local commissioners and providers of healthcare have a responsibility to enable the guideline to be applied when individual professionals and people using services wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties.

 

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.

Share this:

  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to share on Twitter (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to share on Telegram (Opens in new window)
  • Click to email this to a friend (Opens in new window)

Primary Sidebar

Categories

Follow Us

  • Twitter
  • LinkedIn
  • Facebook
  • Instagram
  • Twitter

PIP business directory

Letters to the editor

Letters to the editor

‘PRN’ medicines like Tramadol should never be on repeat

No national Scottish pharmacy flu service a missed opportunity

Pharmacists must leave their comfort zone for the sector to thrive

Why is a decision on the pre-reg exam problem taking so long?

More letters to the editor here...

Blogs

💊 PIP live pharmacy blog

Winter stresses must not ‘destabilise’ general practice

What is it like to depend on medicine to treat endometriosis?

Opinion

Why is pharmacy not integral to government mass vaccination plans?

Pharmacy Covid-19 vaccination involvement is a ‘no-brainer’

The great patient medication returns debacle

CPD Challenges

💊 CPD Challenge: How well do you understand pulmonary embolisms?

💊 CPD Challenge: Prescribing and dispensing clozapine

💊 CPD Challenge: Oral anticoagulants – Dabigatran

More CPD challenges here...

© 2021 · About Pharmacy In Practice · Site mantained by Mike

This site is for healthcare professionals, please confirm you are a healthcare professional to continue.

YES

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
Pharmacy In Practice uses cookies, by continuing to use this site we will assume you are ok with that Find out more.